Overview
- Lonvi says its capsule targets senescent, or 'zombie,' cells using procyanidin C1 (PCC1) derived from grape seeds.
- In company-reported mouse studies, overall lifespan rose 9.4%, and dosing from birth was associated with a 64% extension.
- Chief technology officer Lyu Qinghua told The New York Times that reaching 150 years is 'definitely realistic' and could be possible 'in a few years.'
- The firm promotes the pill as aiming to extend healthy years as well as lifespan by slowing age-related decline.
- Coverage places the claim in a broader Chinese push into longevity science and investment, even as independent validation and any human trials are still absent.